Evotec and Boehringer Ingelheim enter drug discovery deal
Evotec SE will use its PanOmics platform to validate and screen targets and drug candidates in ophtalmology for Boehringer Ingelheim.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
BioNTech and Pfizer evaluate Omicron-specific vaccine
Pfizer Inc and BioNTech SE have started clinical safety testing of an Omikron-specific vaccine in healthy adults 18 through 55 years of age.
Cytovation AS kicks-off with $20m Series A financing
Norway’s immuno-oncology specialist Cytovation A/S has raised $20m in a Series A financing led by early-stage investor Sandwater.
Valneva vaccine neutralises Omicron variant
French-Austrian vaccine specialist Valneva SE has demonstrated that its COVID-19 vaccine induced neutralisation of 87% of the Omicron variant.
Beckman Coulter receives IVDR certification covering more than 200 flow cytometry reagents
Leading the way with the industry’s largest portfolio of CE-IVD labeled flow cytometry reagents in the market, Beckman Coulter Life Sciences announces that it has received a EU Quality Management System Certificate under the new In Vitro Diagnostic Medical Devices Regulation (IVDR) for more than 200 flow cytometry reagents developed and manufactured at their Marseille, France facility.
Neurimmune expands drug discovery collaboration with Ono Pharmaceutical
Swiss Neurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. covering antibody drug targeting neurodegenerative diseases
Evotec and Lilly to collaborate in metabolic diseases
German Evotec SE has entered into a US$1bn drug discovery and development partnership with Eli Lilly and Company in the field of metabolic and renal diseases and diabetes.
Protagen, BioAnalytix and GeneWerk launch ProtaGene
Following their last year announcement to merge, Protagen Protein Services GmbH, BioAnalytix, Inc., and GeneWerk GmbH launch a CRO named ProtaGene.
BioNTech SE licences Cresendo Bio’s Humabody technology
BioNTech and Crescendo Biologics have signed a US-$790m deal to develop multi-specific precision immunotherapies .
Novartis AG executes licence option with Molecular Partners
After Molecular Partners AG reported an 78% reduction of hospitalisation by a single ensovibep dose in infected COVID-19 patients, Novartis AG is to pay a CHF150m milestone.